Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.54 |
| ▸ | YES1 | P07947 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 4/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580732 | 0.79 | SRC (0.55) | SRCPDGFRBYES1ABL1KDR | |
| SCHEMBL41314 | 0.74 | BRAF (0.42) | SRCPDGFRBABL1EGFRKIT | |
| SCHEMBL231130 | 0.74 | SRC (0.78) | SRCPDGFRBYES1ABL1KDR | |
| SCHEMBL231132 | 0.73 | ALK (0.58) | SRCPDGFRBYES1ABL1EGFR | |
| SCHEMBL2579072 | 0.73 | SRC (0.52) | SRCPDGFRBYES1ABL1KDR | |
| SCHEMBL1025214 | 0.72 | SYK (0.65) | SRCPDGFRBABL1EGFRKIT | |
| SCHEMBL1024077 | 0.72 | SYK (0.65) | SRCPDGFRBABL1EGFRKIT | |
| SCHEMBL42295 | 0.72 | BRAF (0.43) | SRCPDGFRBABL1 | |
| SCHEMBL613388 | 0.71 | LRRK2 (0.47) | SRCPDGFRBABL1EGFRKIT | |
| SCHEMBL230383 | 0.70 | SRC (0.54) | SRCPDGFRBYES1ABL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| CN-102333533-A | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS SA | 2012-01-25 | — | — | CN | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| EP-2381943-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | Fovea Pharmaceuticals (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076238-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA (FR) | 2010-07-08 | — | — | WO | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| CN-102333533-A | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS SA | 2012-01-25 | — | — | CN | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | SRC 1325/4885PDGFRB 1013/4885YES1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.